Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Jacqueline Barrientos
View all recent publications

Jacqueline Barrientos

MD
Mount Sinai Medical Center

Academic History

Jacqueline Barrientos, MD, received her medical degree from the Ponce School of Medicine, Ponce, Puerto Rico. She then completed her internal residency at Yale School of Medicine, New Haven, CT, followed by a hematology oncology fellowship at Weill Cornell Medical College, New York City, NY.

Speaking on chronic lymphocytic leukemia (CLL) and lymphoma

Dr Barrientos was involved in the pivotal trials that led to the approval of novel therapeutic agents that target dysregulated pathways in leukemia and lymphoma. She has extensive experience with the novel BTK inhibitors ibrutinib and acalabrutinib, with the PI3Kd inhibitor idelalisib, and the BCL2 inhibitor venetoclax.

Dr Barrientos’s research focus is on CLL and lymphoma. She has served as principal investigator on several Phase I-III clinical trials that lead to the approval of novel therapies, changing the treatment paradigm of CLL and lymphoma.

Ibrutinib combination regimens for CLL from ASH 2017 2:29
Ibrutinib combination regimens for CLL from ASH 2017
Jacqueline Barrientos • 9 Dec 2017
CLL updates from ASH 2017 3:20
CLL updates from ASH 2017
Jacqueline Barrientos • 9 Dec 2017
Are newer, targeted agents better for the management of untreated CLL than chemoimmunotherapy? 2:23
Are newer, targeted agents better for the management of untreated CLL than chemoimmunotherapy?
Jacqueline Barrientos • 9 Dec 2017
Promising future leaders in CLL research 8:40
Promising future leaders in CLL research
Jacqueline Barrientos et al. • 12 May 2017
Recent developments in targeted therapies for chronic lymphocytic leukemia 1:47
Recent developments in targeted therapies for chronic lymphocytic leukemia
Jacqueline Barrientos • 2 Jun 2015
HELIOS trial: Ibrutinib for relapsed/refractory chronic lymphocytic leukemia 2:00
HELIOS trial: Ibrutinib for relapsed/refractory chronic lymphocytic leukemia
Jacqueline Barrientos • 2 Jun 2015
Dose adherence and baseline exposure analysis of ibrutinib for relapsed/refractory CLL 0:52
Dose adherence and baseline exposure analysis of ibrutinib for relapsed/refractory CLL
Jacqueline Barrientos • 8 Sep 2015
Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLL 1:55
Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLL
Jacqueline Barrientos • 8 Sep 2015
Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events 2:21
Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events
Jacqueline Barrientos • 4 Dec 2015
Overview of a promising new study of venetoclax in patients with CLL 3:40
Overview of a promising new study of venetoclax in patients with CLL
Jacqueline Barrientos • 6 Jan 2016
Overview of the Phase I study with acalabrutinib (ACP-196) in CLL 1:08
Overview of the Phase I study with acalabrutinib (ACP-196) in CLL
Jacqueline Barrientos • 4 Dec 2015
Understanding why CLL patients stop responding to treatment, and options for salvage therapies 2:27
Understanding why CLL patients stop responding to treatment, and options for salvage therapies
Jacqueline Barrientos • 6 Jan 2016
iwCLL – International Workshop on Chronic Lymphocytic Leukemia 5:14
iwCLL – International Workshop on Chronic Lymphocytic Leukemia
Federico Caligaris-Cappio et al. • 29 Feb 2016
Current research into drug treatments for CLL – specifically ibrutinib, idelalisib and venetoclax 6:45
Current research into drug treatments for CLL – specifically ibrutinib, idelalisib and venetoclax
Jacqueline Barrientos • 9 Jun 2016
Discussion of a Phase III trial evaluating the efficacy and safety of idelalisib 2:47
Discussion of a Phase III trial evaluating the efficacy and safety of idelalisib
Jacqueline Barrientos • 9 Jun 2016
Overview of CLL therapies and sequencing of therapies 9:00
Overview of CLL therapies and sequencing of therapies
Jacqueline Barrientos • 2 Dec 2016
The content of VJHemOnc is intended for healthcare professionals